Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akari Therapeutics PLC AKTX

Healthcare Biotechnology
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric... see more

Recent & Breaking News (NDAQ:AKTX)

Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin

GlobeNewswire March 31, 2016

Akari Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

GlobeNewswire March 1, 2016

Akari Therapeutics to Participate in the 2016 SunTrust Robinson Humphrey Orphan Drug Day

Press Releases February 17, 2016

Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial

GlobeNewswire January 29, 2016

Akari Therapeutics to Participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day

GlobeNewswire January 27, 2016

Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays

GlobeNewswire January 5, 2016

Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting

GlobeNewswire December 7, 2015

Akari Therapeutics Plc (Nasdaq: AKTX) to Ring the Nasdaq Stock Market Opening Bell

GlobeNewswire December 4, 2015

Akari Therapeutics Announces Upcoming Data Presentations at the 57th American Society of Hematology Annual Meeting

GlobeNewswire November 5, 2015

4 Stocks that Made Huge Moves this Month: Here Are Those that May Continue the Rally

Accesswire November 2, 2015

Akari Therapeutics Closes $75 Million Private Placement

GlobeNewswire September 21, 2015